Q-omics provides the consensus-scored MRPS33 profile across patient tissues and cancer cell-line models. MRPS33 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, MRPS33 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, MRPS33 RNA expression shows 18,004 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight OV, LUAD, and ACC as cancer lineages where MRPS33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPS33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPS33 survival associations across molecular data types. MRPS33 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPS33 RNA expression–survival associations across cancer types. High MRPS33 expression shows unfavorable associations in KICH, CESC, UCS and LIHC, but favorable associations in OV and BLCA. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for MRPS33 RNA expression.
This table summarizes MRPS33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPS33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPS33 shows lower tumor expression in THCA and higher tumor expression in LUAD, LIHC, BLCA, LUSC and BRCA. The LUAD box plot shows higher MRPS33 RNA expression in tumor versus normal tissue (log2 FC = +0.726, t-test p < 0.001).
This table shows molecular features associated with MRPS33 in patient tissues and cancer cell lines. In patient samples, MRPS33 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPS33 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
